Table 1.

Characteristics of the Study Population

	Molnupiravir				Νirmatrelvir/Ritonavir
	Recipients		Nonrecipients		Recipients		Nonrecipients
	No.	%	No.	%	No.	%	No.	%
Outcome
No hospitalization, clinical deterioration, or COVID-19-associated deaths	4022	94.86	3725	87.85	13 462	97.12	12 728	91.83
Hospitalization without ICU admission, clinical deterioration, or death	149	3.51	357	8.42	297	2.14	857	6.18
ICU admission or clinical deterioration	18	0.42	14	0.33	14	0.10	17	0.12
COVID-19–associated death	51	1.20	144	3.40	88	0.63	259	1.87
Hospitalization, ICU admission, clinical deterioration, or death	218	5.14	515	12.14	399	2.88	1133	8.17
Vaccination status
Unvaccinated	534	12.6	859	20.3	1312	9.5	2074	15.0
Single dose	61	1.4	62	1.5	53	0.4	37	0.3
Two doses: before index SARS-CoV-2 infection
≤6 mo	220	5.2	426	10.0	458	3.3	657	4.7
>6 mo	66	1.6	85	2.0	294	2.1	412	3.0
First booster: before index SARS-CoV-2 infection
≤6 mo	3318	78.3	2800	66.0	3533	25.5	3745	27.0
>6 mo	6	0.1	2	0.0	5906	42.6	5681	41.0
Second booster	35	0.8	6	0.1	2305	16.6	1255	9.1
Gender
Male	2128	50.2	2129	50.2	6671	48.1	6462	46.6
Female	2112	49.8	2111	49.8	7190	51.9	7399	53.4
Age, y
65–69	787	18.6	787	18.6	2775	20.0	2775	20.0
70–74	903	21.3	903	21.3	2958	21.3	2958	21.3
75–79	817	19.3	817	19.3	2930	21.1	2930	21.1
≥80	1733	40.9	1733	40.9	5198	37.5	5198	37.5

Abbreviation: ICU, intensive care unit.